Drug profile · INN
cefadroxil/cefadroxil hemihydrate
DURICEF
cefadroxil/cefadroxil hemihydrate (DURICEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — cefadroxil/cefadroxil hemihydrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
cefadroxil/cefadroxil hemihydrate (DURICEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is cefadroxil/cefadroxil hemihydrate?
cefadroxil/cefadroxil hemihydrate (DURICEF) is a bacterial penicillin-binding protein inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for cefadroxil/cefadroxil hemihydrate?
DURICEF is a marketed brand name for cefadroxil/cefadroxil hemihydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cefadroxil/cefadroxil hemihydrate?
cefadroxil/cefadroxil hemihydrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.